- Home
- MMU vs CRMD Comparison
MMU vs CRMD Comparison
Compare MMU & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MMU | CRMD |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 567.5M | 605.9M |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | MMU | CRMD |
|---|---|---|
| Price | $10.65 | $7.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | 129.5K | ★ 1.6M |
| Earning Date | 01-01-0001 | 04-10-2026 |
| Dividend Yield | ★ 4.92% | N/A |
| EPS Growth | N/A | ★ 67.03 |
| EPS | N/A | ★ 1.97 |
| Revenue | N/A | ★ $43,472,170.00 |
| Revenue This Year | N/A | $627.64 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.71 |
| Revenue Growth | N/A | ★ 66363.08 |
| 52 Week Low | $9.46 | $5.60 |
| 52 Week High | $10.71 | $17.43 |
Technical Indicators
Market Signals| Indicator | MMU | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 57.04 | 44.04 |
| Support Level | $9.79 | $6.55 |
| Resistance Level | $10.71 | $8.53 |
| Average True Range (ATR) | 0.08 | 0.26 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 70.45 | 52.43 |
Price Performance
Historical ComparisonAbout MMU Western Asset Managed Municipals Fund Inc.
Western Asset Managed Municipals Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is to maximize current income exempted from federal income tax as is consistent with the preservation of principal. The fund predominantly invests in long-term investment grade municipal debt securities issued by state and local governments, political subdivisions, agencies, and public authorities (municipal obligations).
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.